(Sharecast News) - GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by robust growth in specialty medicines and steady contributions from its vaccines and general medicines divisions.
The FTSE 100 pharmaceutical group reported turnover of £8.55bn for the three months to September, up 7% at actual...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE